Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital PlatformBusiness Wire • 06/22/22
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)GlobeNewsWire • 06/21/22
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase AgreementBenzinga • 06/15/22
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)GlobeNewsWire • 06/15/22
The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our CommunitiesGlobeNewsWire • 06/14/22
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's DiseaseGlobeNewsWire • 06/06/22
Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)GlobeNewsWire • 06/03/22
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALSGlobeNewsWire • 06/03/22
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/02/22
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary EndpointsBusiness Wire • 06/01/22